Merck's business development chief Sunil Patel says the drugmaker wants more deals as it diversifies beyond Keytruda ahead of its 2028 patent cliff.
September 3, 2026 02:49 PM EDT
DealsPharma
Merck's M&A chief expects 'a lot more deal flow' as Keytruda patent cliff nears
Nicole DeFeudis
Merck CEO Robert Davis has been landing deals “with urgency” over the last few years in an effort to shore up the pipeline ahead of …
Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the…
Merck provided some of the clearest direction yet regarding its ambitions in oncology to improve on its blockbuster immunotherapy…
Megadeals are largely missing in an otherwise healthy M&A environment for biopharma.
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year…
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster…
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
